Bluebird bio inc.’s sickle cell disease gene therapy Lyfgenia (lovotibeglogene autotemcel) won US Food and Drug Administration approval on the same day in December as Vertex Pharmaceuticals Incorporated/CRISPR Therapeutics AG’s competing gene-editing medicine Casgevy (exagamglogene autotemcel), but a month later bluebird’s product is in the lead in terms of qualified treatment centers (QTCs) ready to administer the drug and the number of patient lives covered by payers that have agreed to reimburse Lyfgenia’s multimillion-dollar cost.
Key Takeaways
-
Bluebird is in “advanced discussions” with 15 different state Medicaid agencies on Lyfgenia coverage.
-
Outcomes-based agreements with state and private payers may follow expected publication of value rationale for Lyfgenia’s $3.1m price tag.
-
Despite its higher price, Lyfgenia to date has 35 qualified treatment centers ready to administer the sickle cell gene therapy in the US versus nine centers ready to administer Vertex/CRISPR’s gene-editing medicine Casgevy
The company said when it won FDA approval for its beta-thalassemia gene therapy Zynteglo (betibeglogene autotemcel) in August 2022 that the product’s launch would lay the commercial groundwork for its other gene therapies, particularly for its sickle cell disease program
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?